SYRE
Spyre Therapeutics, Inc.
There isn't enough reported data to score SYRE yet.
SYRE Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Unavailable |
SYRE's revenue and profitability are currently weak. There isn't enough data to rate its cash flow and balance sheet.
SYRE PE Valuation
SYRE has no meaningful PE right now: it lost money over the past year.
SYRE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| -- | |
| -- | |
| Limited | |
| Low |
Analysts expect SYRE's losses to grow, with revenue holding steady. However, they disagree widely on these estimates.
SYRE Earnings Per Share
SYRE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2023 | $688K | +10% |
| Q1 2023 | $198K | -85% |
| Q4 2022 | $168K | -95% |
| Q3 2022 | $174K | -88% |
| Q2 2022 | $625K | -95% |
SYRE's revenue has slid since its 2021 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2023 | -23146% | -19559 points |
| Q1 2023 | -9498% | -7704 points |
| Q4 2022 | -11406% | -10845 points |
| Q3 2022 | -10779% | -9328 points |
| Q2 2022 | -3588% | -3539 points |
| Q1 2022 | -1794% | N/A |
| Q4 2021 | -561% | N/A |
| Q3 2021 | -1451% | N/A |
SYRE's operating margin was −23146% last quarter, down 19559 points from the same quarter a year ago, near the bottom of its range since 2021.
SYRE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$77.5M | -$40.4M |
| Q2 2026 | -$69.9M | -$23.3M |
| Q1 2026 | -$57.4M | -$16.4M |
| Q3 2025 | -$37.1M | -$7.7M |
| Q2 2025 | -$46.6M | +$15.7M |
| Q1 2025 | -$41M | -$12.5M |
| Q4 2023 | -$31M | -$12.9M |
| Q4 2022 | -$18.1M | +$1.1M |
SYRE has burned cash in almost every quarter: −$249M over the past year, against −$154M the year before.
SYRE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7.7% | +6.8M shares |
| 1 year | +22% | +17.4M shares |
SYRE has 95M diluted shares, up 22% from a year ago.
SYRE Net Leverage
SYRE's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
SYRE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 63.3 | Neutral |
| Stochastic | 72.4 | Neutral |
SYRE's weekly RSI is 63 (neutral) and its Stochastic is 72 (neutral).
SYRE PE vs Healthcare Sector
SYRE has no meaningful PE right now: it lost money over the past year.
SYRE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $92.3 | 12% above |
| 20 week MA | $94.9 | 8.4% above |
| 50 week MA | $69.1 | 49% above |
| 100 week MA | $43.8 | 135% above |
| 200 week MA | $32.2 | 220% above |
SYRE is in an uptrend: it's above all five of its weekly moving averages, and 220% above its 200-week average.
SYRE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $197.5 | $203.3 | +2.9% |
| 2021 | $203.3 | $105.3 | -48% |
| 2022 | $105.3 | $8.98 | -91% |
| 2023 | $8.98 | $21.5 | +140% |
| 2024 | $21.5 | $23.7 | +10% |
| 2025 | $23.7 | $32.9 | +39% |
| 2026 YTD | $32.9 | $102.9 | +212% |
SYRE's yearly returns have swung widely, from +140% in 2023 to −91% in 2022. It's up 212% so far in 2026.